Long-term Neurovascular Complications After Radiation Therapy in Head and Neck Cancer

Sponsor
Chang Gung Memorial Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06111430
Collaborator
(none)
800
1
48
16.7

Study Details

Study Description

Brief Summary

Head and neck cancer is a group of cancers develop from the soft tissues, salivary gland, mucosa of the upper respiratory or digestive system covering the oral and nasal cavity. Radiotherapy is usually the standard treatment of Head and neck cancers. In the present study, investigators aim to study the prevalence of cervical-cranial vascular complications during the early stages in these Head and neck cancer patients receiving Radiotherapy. Investigators will also compare the results between Nasopharyngeal cancer and other Head and neck cancerpatients receiving Radiotherapy.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    800 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Ambidirectional Cohort Study of Neurovascular Complications After Radiation Therapy in Head and Neck Cancer Patients
    Actual Study Start Date :
    Apr 11, 2022
    Actual Primary Completion Date :
    Apr 10, 2023
    Anticipated Study Completion Date :
    Apr 10, 2026

    Outcome Measures

    Primary Outcome Measures

    1. Significant CAS at internal carotid artery or common carotid artery [1 year]

      We define significant CAS as (a) >50% stenosis on the B-mode with peak systolic velocities ≥120 cm/s based on the hemodynamic criteria at any internal carotid artery or common carotid artery in the CDU study according to the standard ultrasound criteria35; or (b) > 50% diameter stenosis on the follow up CT or MR images.

    2. Cerebral infarctions (CI) [1 year]

      The CI is defined whenever there were symptomatic IS occurrence of presence of asymptomatic IS on the reviewed brain MRIs.

    3. Significant extracranial vertebral artery stenosis (VAS) [1 year]

      > 50% diameter stenosis on the follow up CT or MR images.

    4. Significant intracranial artery stenosis [1 year]

      Presence of > 50% stenosis at intracranial ICA/VA, basilar artery, middle cerebral artery, anterior cerebral artery, or anterior cerebral artery.

    5. Presence of carotid blow-out syndrome [1 year]

      Carotid blow out syndrome was categorized as type 1 (threaten type), type 2 (impending blowouts), and type 3 (acute CBS hemorrhage).

    6. Presence of TLN [1 year]

      We will identify white matter lesions, contrast-enhanced lesions, Cysts, and local mass effect. The white matter lesions in the temporal lobe will be divided into three groups: mild (small focal areas), moderate (larger confluent areas) and severe (large confluent areas extending outside the radiation field with or without local mass effect). The cysts will be evaluated for size and number. The local mass effect will be classified as mild (affecting only the temporal lobe sulci), moderate (affecting the sulci and ventricles) and severe (affecting the midline of the brain).

    7. Presence of hypothyroidism [1 year]

      Clinical hypothyroidism was diagnosed when a patient had free T4 ≤ 0.80 ng/dL with elevated TSH (>5.0 mU/L).

    8. Tumor recurrence [1 year]

      Relapse

    9. Mortality [1 year]

      Death

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Population: Prospective cohort

    Inclusion Criteria:
    1. Age ≥20 years.

    2. Head and neck cancer patient .

    3. Had ever received radiation therapy (RT) ≦ 72 months before inclusion in the registry.

    4. Had ≥ 1 brain images and cervical-cranial vascular studies between the end of RT and d date of enrolment.

    Exclusion Criteria:
    1. Age <20 years.

    2. Patients not willing to sign the informed consent.

    Population: Retrospective validation cohort

    Inclusion Criteria:
    1. Age ≥20 years.

    2. Head and neck cancer patient.

    3. Had ever received radiation therapy (RT) > 120 months before the adoption date of IRB at the participant site.

    4. Had ≥ 2 brain images and cervical-cranial vascular studies between the end of RT and 6~10 years after RT, one within 5 years after RT, the other after 5 years after RT.

    Exclusion Criteria:

    1.Age <20 years.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chang Gung Memorial Hospital Taipei Taiwan

    Sponsors and Collaborators

    • Chang Gung Memorial Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Chang Gung Memorial Hospital
    ClinicalTrials.gov Identifier:
    NCT06111430
    Other Study ID Numbers:
    • 202200464B0
    First Posted:
    Nov 1, 2023
    Last Update Posted:
    Nov 1, 2023
    Last Verified:
    Apr 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 1, 2023